Biomarkers Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Large pharma companies at Biomarkers Europe 2026
Oct 13–14, 2026 Basel, Switzerland ~1k attendees Website
11 large pharma companies are at Biomarkers Europe 2026 — 41 presentations on the program. Most represented: Novartis (8 on the program), AstraZeneca (4 on the program), Merck Healthcare (4 on the program). 9 of them have their own page in this guide. As of Oct 8, 2026.
Topic
Top represented
Showing 1–10 of 11 organizations
| Organization | Biomarkers Europe 2026 Attendance |
|---|---|
Novartis Basel, Switzerland | |
Swiss pharmaceutical company with marketed medicines in oncology, immunology, neuroscience and cardiovascular disease. | Talk Tue Oct 13 9:15am–9:40am Precision Medicine Beyond the Hype: Delivering Real Clinical Impact Drug–diagnostic commercialization & access Panel Tue Oct 13 12:40pm–1:30pm Application And Integration Of Proteomic Biomarkers In Precision Medicine Genomics, proteomics and multi-omicsBiomarker discovery & translation Talk Tue Oct 13 2:30pm–2:55pm Spatial Autoimmunity - Challenges and Opportunities in Salivary Glands Digital pathology & spatial biomarkers Talk Tue Oct 13 2:55pm–3:20pm Translational Biomarkers For Evaluating Biologic Drug Efficacy Biomarker discovery & translation Talk Tue Oct 13 3:20pm–3:45pm Leveraging UK Biobank to Derive Proteomic Signatures Representative of Disease Biology of Dermatological Indications Genomics, proteomics and multi-omics Talk Wed Oct 14 9:10am–9:35am Digital Health Technology Adoption In Clinical Development Multimodal & AI-enabled precision medicineDrug–diagnostic commercialization & access Panel Wed Oct 14 1:00pm–1:30pm Biomarker Strategies In Neurodegenerative Therapeutics Biomarker discovery & translation Panel Wed Oct 14 3:15pm–4:05pm AI-Enabled Clinical Trial Innovation - From Biomarker Data To Decision Multimodal & AI-enabled precision medicine |
AstraZeneca Cambridge, UK | |
Global pharmaceutical company developing and marketing medicines in oncology, cardiovascular, renal, respiratory and rare diseases. | Talk Tue Oct 13 9:15am–9:40am From Digital Pathology To Precision Medicine: Scaling AI-Driven Image Analysis Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Tue Oct 13 12:40pm–1:30pm Application And Integration Of Proteomic Biomarkers In Precision Medicine Genomics, proteomics and multi-omicsBiomarker discovery & translation Panel Tue Oct 13 12:40pm–1:30pm Overcoming Challenges In Deploying Foundation Models, LLMs And Agentic AI For Pathology Workflows Multimodal & AI-enabled precision medicineDigital pathology & spatial biomarkers Panel Tue Oct 13 5:10pm–6:00pm AI-Powered Precision Medicine Multimodal & AI-enabled precision medicine Panel Wed Oct 14 8:05am–8:30am Bringing Digital & AI Into The Clinic: How To Globalise Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 14 11:45am–12:10pm Digital Biomarkers, Cancer Networks And Clinical Action Multimodal & AI-enabled precision medicine Panel Wed Oct 14 1:00pm–1:30pm Deploying Computational Pathology Across The Pharma Pipeline Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine |
Merck Healthcare Darmstadt, Germany | |
Healthcare business of Merck KGaA, Darmstadt, developing and marketing medicines in oncology, neurology, immunology and fertility. | Talk Tue Oct 13 11:50am–12:15pm Precision Medicine: Drug/CDx Regulatory Strategy In The US And EU Clinical & companion diagnostic development Panel Tue Oct 13 12:40pm–1:30pm IVDR Regulations & Their Impact Clinical & companion diagnostic development Talk Tue Oct 13 2:30pm–2:55pm Profiling Tumor-Associated Antigens - A Screening Approach Using Spatial Highplex IF Digital pathology & spatial biomarkers Talk Tue Oct 13 2:55pm–3:20pm To Multiplex Or Not To Multiplex- The Question In Preclinical Drug Development Biomarker discovery & translation Talk Wed Oct 14 8:40am–9:10am From Data To Design: AI-Driven Generative Biology And The Future Of Personalized Medicine Multimodal & AI-enabled precision medicine Panel Wed Oct 14 3:15pm–4:05pm AI-Enabled Clinical Trial Innovation - From Biomarker Data To Decision Multimodal & AI-enabled precision medicine |
Roche Basel, Switzerland | |
Swiss healthcare group whose pharmaceuticals division develops medicines in oncology, neuroscience, immunology and other areas. | Talk Tue Oct 13 11:50am–12:15pm Computational Co-Intelligence - Closing The Gap Between Technology And Patients' Needs Multimodal & AI-enabled precision medicine Talk Tue Oct 13 12:15pm–12:40pm From Spatial Biology To Therapeutic Insight: Lessons From Alzheimer’s Disease And Oncology Digital pathology & spatial biomarkers Panel Tue Oct 13 12:40pm–1:30pm Overcoming Challenges In Deploying Foundation Models, LLMs And Agentic AI For Pathology Workflows Multimodal & AI-enabled precision medicineDigital pathology & spatial biomarkers Panel Tue Oct 13 5:10pm–6:00pm AI-Powered Precision Medicine Multimodal & AI-enabled precision medicine Talk Wed Oct 14 11:45am–12:10pm Stain Transfer for Pathology: Learning Cross Stain Representations from H&E Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine |
Lundbeck Copenhagen, Denmark | |
Danish pharmaceutical company focused on brain diseases, with medicines in psychiatry, neurology and migraine. | Talk Tue Oct 13 8:45am–9:15am New Frontiers In Precision Medicine – The Neurology Example Biomarker discovery & translation Panel Tue Oct 13 1:05pm–1:30pm Translating Biomarkers From Discovery To Clinical Use Biomarker discovery & translation Panel Wed Oct 14 1:00pm–1:30pm Biomarker Strategies In Neurodegenerative Therapeutics Biomarker discovery & translation Talk Wed Oct 14 4:05pm–4:30pm Using Biomarkers To Drive Decision-Making In Neurodegenerative Diseases Biomarker discovery & translation |
Sanofi Paris, France | |
French pharmaceutical company with medicines and vaccines in immunology, rare diseases, neurology and oncology. | Talk Tue Oct 13 11:50am–12:15pm Untargeted Biomarker Discovery For Toxicological & Pharmacological Investigations In Pre-Clinical Drug Discovery Programs By Spatial Tissue Mass Spectroscopy Imaging Platform Biomarker discovery & translationDigital pathology & spatial biomarkers Talk Tue Oct 13 12:15pm–12:40pm Clinical Trial Outcome Prediction Through Systematic Data Enrichment: Integrating Pharmacokinetic And Biomarker Data Multimodal & AI-enabled precision medicine |
AbbVie North Chicago, IL | |
Global biopharmaceutical company with marketed medicines in immunology, oncology, neuroscience and aesthetics. | Talk Tue Oct 13 9:15am–9:40am A Regulatory Perspective on the Expanding Reach of Personalized Medicine Clinical & companion diagnostic development Panel Tue Oct 13 12:40pm–1:30pm IVDR Regulations & Their Impact Clinical & companion diagnostic development Panel Wed Oct 14 1:00pm–1:30pm From Silos To Alliances – Rethinking Collaboration In Precision Medicine Drug–diagnostic commercialization & access |
GSK London, UK | |
Global pharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology. | Talk Tue Oct 13 2:55pm–3:20pm AI-Powered Biomarkers And The Next Wave Of Innovation In Precision Oncology Multimodal & AI-enabled precision medicine Panel Tue Oct 13 5:10pm–6:00pm AI-Powered Precision Medicine Multimodal & AI-enabled precision medicine |
UCB Brussels, Belgium | |
Belgian biopharmaceutical company with marketed medicines in immunology and neurology, including epilepsy and autoimmune diseases. | Panel Wed Oct 14 1:00pm–1:30pm Deploying Computational Pathology Across The Pharma Pipeline Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 14 3:40pm–4:05pm Artificial Intelligence For Non-Clinical Safety: Past, Present And The Long Road Ahead Multimodal & AI-enabled precision medicine |
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned pharmaceutical company developing human and animal health medicines, including cardiometabolic, respiratory, oncology and mental health drugs. | Talk Tue Oct 13 11:50am–12:15pm Liquid Biopsy Approaches Using Urinary Biomarkers In CKD Drug Development Liquid biopsy & MRDBiomarker discovery & translation |
Instantly find 20 buyers from large pharma companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Biomarkers Europe 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by Biomarkers, CDx & Precision Medicine or its organizers. Submit a correction